Michael May is the Interim Chief Executive Officer of OmniaBio Inc. Under his leadership, OmniaBio is accelerating the development and commercialization of transformative therapies, helping to expand access and affordability across the world while reinforcing Canada’s role as a global CGT innovation hub. 

Dr. May is also President, CEO, and co-founder of CCRM, a public-private partnership focused on advancing regenerative medicine and enabling technologies. Since founding CCRM in 2011, he has built a global network of researchers, companies, and investors to translate scientific breakthroughs into market-ready therapies. In 2022, CCRM launched OmniaBio as a commercial-stage CDMO, leveraging over a decade of expertise in manufacturing, analytics, and AI-driven process development. 

Dr. May earned his Ph.D in Chemical Engineering from the University of Toronto, where he was an NSERC Scholar and recipient of the Martin Walmsley Fellowship for Technological Entrepreneurship. In 2023, he was honoured with the Le Prix Luc Sensebé Innovation and Leadership Award by the International Society for Cell and Gene Therapy, recognizing his impact on the field.